-Bloomberg
Baird Downgrades Vir Biotechnology to Underperform, Announces $36 Price Target
Baird analyst Joel Beatty downgrades Vir Biotechnology (NASDAQ:VIR) from Neutral to Underperform and announces $36 price target.
Related Posts
Goldman Sachs Initiates Coverage On Membership Collective with Neutral Rating, Announces Price Target of $16
Goldman Sachs analyst Stephen Grambling initiates coverage on Membership Collective (NYSE:MCG) with a Neutral rating and announces Price Target of $16.
Read Why Tigress Financial Remains Bullish On Intel
Tigress Financial analyst Ivan Feinseth raised the price target on Intel Corp (NASDAQ:INTC) to $72 from $68 and reiterated a Buy. The price…
Goldman Sachs Downgrades American Water Works Co to Neutral, Lowers Price Target to $177
Goldman Sachs analyst Insoo Kim downgrades American Water Works Co (NYSE:AWK) from Buy to Neutral and lowers the price target from $191 to $177.